1
|
Xu M, Liu X, Li P, Yang Y, Zhang W, Zhao S, Zeng Y, Zhou X, Zeng LH, Yang G. Modified Natriuretic Peptides and their Potential Role in Cancer Treatment. Biomed J 2021; 45:118-131. [PMID: 34237455 PMCID: PMC9133251 DOI: 10.1016/j.bj.2021.06.007] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Revised: 06/07/2021] [Accepted: 06/28/2021] [Indexed: 01/20/2023] Open
Abstract
The natriuretic peptide family (NPs) is a group of natural endocrine hormones, containing a 17-amino acid ring structure connected by disulfide bonds of two cysteines. In this review, the members of the natriuretic peptide family and their corresponding receptors as well as the anti-cancer effects are introduced. Four cardiac hormones of NPs (ANP, VD, KP and LANP) can effectively inhibit the growth of human small cell lung cancer, breast cancer and other tumors and significantly reduce tumor volume in vivo. The in vitro experiments also show that cardiac hormones, CNP and urodilatin can effectively inhibit the growth of most tumor cells. We then further summarized the anti-cancer mechanism of natriuretic peptides. Finally, we introduce several methods that modify natriuretic peptides, leading to enhance their stability and prolong the biological effects of these peptides, which might be helpful for the clinical application in the future. Peptide therapy is a very promising field for cancer treatments since they can induce the death of cancer cells without dramatically affecting normal cells. The synthesis of a useful and stable natriuretic peptide can enhance the effect of cancer treatments and significantly reduce drug resistance and toxicity.
Collapse
Affiliation(s)
- Mengjiao Xu
- School of Bioengineering, Hangzhou Medical College, Hangzhou, 310013, China; Department of Pharmacology, School of Medicine, Zhejiang University City College, Hangzhou, 310015, China
| | - Xingzhu Liu
- School of Bioengineering, Hangzhou Medical College, Hangzhou, 310013, China
| | - Ping Li
- School of Bioengineering, Hangzhou Medical College, Hangzhou, 310013, China
| | - Yadong Yang
- School of Bioengineering, Hangzhou Medical College, Hangzhou, 310013, China
| | - Wenyuan Zhang
- School of Bioengineering, Hangzhou Medical College, Hangzhou, 310013, China
| | - Siyu Zhao
- School of Bioengineering, Hangzhou Medical College, Hangzhou, 310013, China
| | - Ying Zeng
- Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310006, China
| | - Xile Zhou
- Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310006, China
| | - Ling-Hui Zeng
- Department of Pharmacology, School of Medicine, Zhejiang University City College, Hangzhou, 310015, China
| | - Geng Yang
- Department of Pharmacology, School of Medicine, Zhejiang University City College, Hangzhou, 310015, China.
| |
Collapse
|
2
|
Aleck K, Hallman K, Quigley M, Lloyd V, Szmyd M, Ruskin D, Bedgood T, Dinda S. Effects of Atrial Natriuretic Peptide on p53 and Estrogen Receptor in Breast Cancer Cells. Biores Open Access 2017; 6:141-150. [PMID: 29098120 PMCID: PMC5665415 DOI: 10.1089/biores.2017.0009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
The atrial natriuretic peptide (ANP) hormone is secreted by cardiac atrial myocytes and acts to regulate blood pressure homeostasis in humans. Previous research indicates ANP treatment significantly decreases the proliferation of human prostate cancer cells, pancreatic adenocarcinoma, and breast cancer cells. Minimal studies have been conducted with regard to ANP regulating tumor suppressor genes and steroid hormone receptors in breast cancer cells. Our study analyzed the effects of ANP in combination with 17β-estradiol (E2) and antiestrogen treatments on p53 and ERα levels in T-47D breast cancer cells. Preliminary studies through Western blot analysis showed that ANP treatment decreases p53 and ERα expression levels in a concentration-dependent (10-100 nM) manner. Treatment with ANP alone, at a 100 nM concentration, causes a decrease of p53 and ERα expression compared with Cs (control stripped), but with E2 and antiestrogen combinations, expression of both protein levels decreased compared with treatments without ANP. Combined treatment with E2, an estrogen antagonist, and ANP decreased cellular proliferation compared with treatments without ANP, except in the case of raloxifene (RAL). Our studies indicate that ANP has potential as a therapeutic breast cancer treatment and should inspire further studies on the molecular mechanism of ANP in T-47D breast cancer cells.
Collapse
Affiliation(s)
- Katie Aleck
- Department of Biomedical Diagnostic Therapeutic Sciences, School of Health Sciences, Institute for Stem Cell Research and Center for Biomedical Research, Oakland University, Rochester, Michigan
| | - Kelly Hallman
- Department of Biomedical Diagnostic Therapeutic Sciences, School of Health Sciences, Institute for Stem Cell Research and Center for Biomedical Research, Oakland University, Rochester, Michigan
| | - Meghan Quigley
- Department of Biomedical Diagnostic Therapeutic Sciences, School of Health Sciences, Institute for Stem Cell Research and Center for Biomedical Research, Oakland University, Rochester, Michigan
| | - Victoria Lloyd
- Department of Biomedical Diagnostic Therapeutic Sciences, School of Health Sciences, Institute for Stem Cell Research and Center for Biomedical Research, Oakland University, Rochester, Michigan
| | - Monica Szmyd
- Department of Biomedical Diagnostic Therapeutic Sciences, School of Health Sciences, Institute for Stem Cell Research and Center for Biomedical Research, Oakland University, Rochester, Michigan
| | - Dana Ruskin
- Department of Biomedical Diagnostic Therapeutic Sciences, School of Health Sciences, Institute for Stem Cell Research and Center for Biomedical Research, Oakland University, Rochester, Michigan
| | - Tyler Bedgood
- Department of Biomedical Diagnostic Therapeutic Sciences, School of Health Sciences, Institute for Stem Cell Research and Center for Biomedical Research, Oakland University, Rochester, Michigan
| | - Sumi Dinda
- Department of Biomedical Diagnostic Therapeutic Sciences, School of Health Sciences, Institute for Stem Cell Research and Center for Biomedical Research, Oakland University, Rochester, Michigan
| |
Collapse
|
3
|
Serum atrial natriuretic peptide: a suspected biomarker of breast cancer. Contemp Oncol (Pozn) 2017; 21:54-59. [PMID: 28435399 PMCID: PMC5385479 DOI: 10.5114/wo.2017.66657] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2016] [Accepted: 01/06/2017] [Indexed: 12/13/2022] Open
Abstract
Aim of the study To assess serum levels of ANP in breast cancer female patients and its relationship to metastasis and some clinical parameters among those patients. Material and methods One hundred breast cancer patients with and without metastasis along with 20 healthy closely matched controls, were enrolled in the present cross sectional study. Background: To assess the serum levels of atrial natriuretic peptide in breast cancer Serum levels of ANP were assessed using ELISA. Results Mean serum levels of ANP breast cancer patients (13.9 ±10.1 ng/ml) were significantly elevated compared to healthy control group (2.2 ±1.3 ng/ml) (p < 0.001). The metastatic breast cancer patients showed significant elevated ANP levels (17.1 ±8.9 ng/ml) compared to non-metastatic group (6.4 ±8.8 ng/ml) p < 0.001. Within the metastatic group significant difference was detected between de novo metastatic, under follow-up, under hormonal control and locally advanced group (p = 0.007). Conclusions This study showed significant elevated levels of ANP in the serum of metastatic breast cancer patients compared to non-metastatic patients. Within the metastatic group the lowest levels were detected in metastatic breast Cancer under hormonal treatment either tamoxifen or aromatase inhibitor.
Collapse
|